Category

Private Companies

Aug 12
Love0

F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent

By F2G, Press Release, Private Companies
Press Release.

 

Financing round led by Cowen Healthcare Investments with strong support from existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences

MANCHESTER, UK / VIENNA, Austria – 12th August 2020 – F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections, announced today that it has secured US $60.8 million in new financing from new and existing investors. The financing round is led by Cowen Healthcare Investments and includes strong participation from existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences.

Proceeds from the financing will be used to fund F2G’s late-stage clinical programs for their novel antifungal agent olorofim and organisational scale-up in preparation for commercialisation.

Olorofim (formerly F901318) is F2G’s lead candidate and is in a Phase 2b open-label study focussing on rare and resistant life-threatening invasive fungal infections, such as invasive aspergillosis (including azole-resistant strains), scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis, and coccidioidomycosis (Valley Fever). Olorofim was granted Breakthrough Therapy designation (BTD) for the indication of ‘Treatment of invasive mold infections in patients with limited or no treatment options, including aspergillosis refractory or intolerant to currently available therapy, and infections due to Lomentospora prolificans, Scedosporium, and Scopulariopsis species’ in November 2019 by the US Food and Drug Administration (FDA), the only antifungal agent ever to have been awarded this status. Olorofim has the potential to be the first truly novel mechanism antifungal therapy for nearly twenty years and represents a very significant market opportunity in an area of high unmet clinical need.

Commenting on the news, Ian Nicholson, CEO of F2G Ltd, said:

“Following a successful year during which F2G has received FDA Breakthrough Therapy designation for olorofim, as well as FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever), and QIDP designation in multiple fungal infections, today’s announcement is a significant milestone. We are delighted to welcome Cowen Healthcare Investments to F2G, and I would like to thank our existing investors for their continued support. This financing marks the continued commitment of our shareholders and paves the way for the advanced development and potential approval of the first new antifungal treatment in 20 years, offering hope for patients with very limited treatment options and a high medical need.”

Tim Anderson, Managing Director at Cowen Healthcare Investments said:

“The necessity for the discovery and development of treatments to tackle infectious diseases is today more apparent than ever. F2G’s antifungal candidate demonstrates significant promise in terms of safety, tolerability, and efficacy. With our focus on supporting transformational science that can deliver real clinical outcomes, we are pleased to work with this proven management team and group of renowned investors to build on F2G’s significant scientific and commercial potential.”

Joining the F2G Board in conjunction with the financing will be Tim Anderson, Managing Director at CHI, Will West, Investment Advisor at Morningside Ventures and Naveed Siddiqi, Partner at Novo Ventures. Naveed takes over from Martin Edwards who is retiring from the Board.

Ian Nicholson added:

“We welcome Tim Anderson, Will West and Naveed Siddiqi who replaces Martin Edwards as the representative of Novo Holdings on the Board of Directors. On behalf of the Board we would like to thank Martin for his contribution to F2G. His industry expertise and counsel have been instrumental in guiding F2G through recent developmental and financing milestones, and we wish him the very best.”

Contact:

F2G Ltd
Ian Nicholson | Chief Executive Officer
Ralf Schmid | Chief Financial Officer
Tel: +44 (0)161 785 1271 (UK) / +43 (0)1 997 4267 (A)

Optimum Strategic Communications
Mary Clark / Supriya Mathur / Charlotte Hepburne-Scott
Tel: +44 (0) 203 922 0891
Email: F2G@optimumcomms.com

Notes to Editors:

About F2G
F2G is a world-leading UK- and Austria-based biotech company (F2G Ltd and F2G Biotech GmbH)
focused on the discovery and development of novel therapies to treat life-threatening invasive fungal
infections. F2G has discovered and developed a completely new class of antifungal agents called the
orotomides. The orotomides target dihydroorotate dehydrogenase (DHODH), a key enzyme in the de
novo pyrimidine biosynthesis pathway. This is a completely different mechanism from that of the
currently marketed antifungal agents and gives the orotomides fungicidal activity against a broad range
of rare and resistant fungal mould infections. Olorofim (formerly, F901318) is F2G’s leading candidate
from this class. www.f2g.com

About Olorofim
Olorofim is currently being investigated in an open-label single-arm Phase 2b study (ClinicalTrials.gov
Identifier: NCT03583164) in patients with proven invasive fungal disease (IFD) or probable invasive
aspergillosis (IA) with limited treatment options (refractory disease, resistance, or intolerance to
available agents). On 7 November 2019, olorofim was granted Breakthrough Therapy designation (BTD)
by the US Food and Drug Administration (FDA), the only antifungal agent ever to have been awarded
this status.

About Cowen Healthcare Investments
Cowen Healthcare Investments invests fiduciary capital in private healthcare companies across the
biopharma, diagnostics and digital health sectors. Cowen Healthcare Investments is a strategy of Cowen
Investment Management, which develops differentiated, actively managed products on behalf of its
clients. Cowen Investment Management is a division of Cowen Inc. Learn more at www.cowen.com

Back

Aug 12
Love0

PIC Therapeutics Appoints Dr. Katherine Bowdish as Chief Executive Officer

By PIC Therapeutics, Press Release, Private Companies
Press Release.

 

NATICK, MA – August 12, 2020 – PIC Therapeutics (“PIC”), a biotechnology company
focused on transforming the treatment of cancer through the selective modulation of
oncogene translation, today announced the appointment of Katherine Bowdish, Ph.D.,
as its President and Chief Executive Officer. Dr. Bowdish will also join the Board of
Directors of PIC.

Dr. Bowdish brings more than 20 years of biopharmaceutical business and scientific
leadership to PIC Therapeutics. Kathy was most recently at Sanofi, where she
launched and led Sanofi Sunrise, a venture investment and partnering vehicle to
accelerate early stage pioneering science for patients benefit through unique
relationships with leading entrepreneurs, and more recently served as Vice President
and Head of R&D Strategy. Prior to her leadership roles at Sanofi, Kathy co-founded or
led several early-stage life science companies focused on biological therapies.
Kathy’s positions include President & CSO, Permeon Biologics; Co-founder, President
& CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice
President, Alexion Pharmaceuticals; and Founder, CEO & CSO, Prolifaron, prior to its
acquisition by Alexion.

Kathy has served on the Boards of Directors of MyoKardia, Warp Drive Bio, Portal
Instruments, Thermalin, Permeon Biologics, Anaphore and Prolifaron, and most
recently served as an Observer on the DiCE Molecules Board. Kathy received her
Ph.D. in molecular genetics from Columbia University College of Physicians and
Surgeons, and her B.Sc. degree from the College of William and Mary.

“We are thrilled to have Dr. Bowdish joining PIC as CEO. Her proven strategic leadership
and investment experience will be vital to realizing the full potential of PIC’s scientific
platform as it advances PIC’s drug candidates toward human clinical studies,” stated PIC
Therapeutics’ Executive Chairman, Alan Walts. “Kathy additionally has deep experience
in developing the kind of innovative strategic partnerships that will be a critical part of
PIC’s success.”

“The promise of addressing broad-based genomic anomalies in cancer through
modulating translation of oncogene RNA provides a unique opportunity to create
impactful new therapies for patients with cancer,” said Dr. Bowdish. “I am excited to be
joining the PIC Therapeutics team and look forward to leading the company as we
advance drug candidates through remaining preclinical and translational studies, and
into the clinic for patients in need.”

About PIC Therapeutics

PIC Therapeutics is a Natick, MA-based biotechnology company focused on
fundamentally changing how we treat cancer by developing a new generation of
therapeutics based on the modulation of RNA translation. PIC’s therapeutics target the
“master switch” of cancer signaling pathways, selectively blocking oncogene protein
production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA
translation. PIC Therapeutics’ selective approach has the potential to simultaneously
modulate multiple oncogenic drivers leading to a powerful new generation of cancertreating
therapeutics that address drug resistance and tumor heterogeneity, issues that
plague many existing treatments. For more information visit www.pictherapeutics.com.

PIC is guided by a dedication to improving cancer patient outcomes and to realizing the
potential of our technology to their benefit.

Contact:
Kathy Bowdish
kbowdish@pictherapeutics.com
(617) 528-8715

Jun 24
Love0

Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158

By Artax Biopharma, Press Release, Private Companies
Press Release.

 

Renowned Global Leaders are Experts in Immunology, Autoimmune Disease, and T Cell Signaling

Cambridge, Mass., June 24, 2020 – Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the formation of their Scientific Advisory Board (SAB). The SAB is comprised of experts in Immunology, Autoimmune Disease, and T Cell Signaling, and was formed to guide the company as it proceeds into future clinical trials with a first-in-class, oral small molecule autoimmune disease immunomodulator AX-158.

Artax Biopharma is poised to enter clinical trials with the small molecule AX- 158, a novel approach to treat multiple autoimmune diseases without causing the immunosuppression commonly associated with current autoimmune disease therapies.

Balbino Alarcón, PhD, Chairman of Artax’s Scientific Advisory Board, commented,

“I am privileged to lead Artax’s Scientific Advisory Board, which mobilizes global leaders in Immunology, Autoimmune Disease, and T Cell Signaling. Collectively we are enthusiastic to collaborate on, and contribute to, important development initiatives related to Artax’s innovative approach to autoimmune disease treatment.”

“Artax Biopharma’s Nck inhibitor AX-158 has shown impressive experimental biologic and mechanistic impact on T cell modulation – managing autoimmune disease without inducing the profound immunosuppression or interference with memory response associated with conventional or biological therapies,”

stated Dr. Lawrence Steinman, Stanford University Zimmerman Professor of Neurology and Neurosciences, Pediatrics, and Genetics and Scientific Advisory Board member.

“Convening a Scientific Advisory Board is a critical step as we accelerate our clinical development program,”

stated Artax Biopharma Chief Executive Officer Joseph Lobacki.

“The clinical expertise and knowledge of these experts is unparalleled and will be instrumental in informing our development strategy across several autoimmune diseases.”

The SAB will be comprised of five experts, and is being led by
Professor Balbino Alarcón, PhD, co-founder of Artax Biopharma:

Balbino Alarcón, PhD
Dr. Alarcón is Program Director at the National Research Council of
Spain (CSIC) and Head of the TCR-mediated Signal Transduction
Laboratory.

Raif Geha, MD
Dr. Geha is the James L. Gamble Professor of Pediatrics at Harvard
Medical School and Chief of the Allergy/Immunology/Rheumatology and
Dermatology Division at Children’s Hospital in Boston.

Menno de Rie, MD
Prof. de Rie is a board-certified dermatologist and vice-chair of the
department of Dermatology of the Amsterdam University Medical Centres/
University of Amsterdam.

Lawrence Steinman, MD
Dr. Steinman is the George A. Zimmermann professor of Neurology
and Neurological Sciences, Pediatrics, and Genetics at Stanford University.

Cox Terhorst, PhD
Dr. Terhorst is Chief of Immunology at Beth Israel Deaconess Medical
Center and Professor at Harvard Medical School.

About Immunomodulation
A healthy immune system eliminates harmful foreign pathogens, while
being tolerant of self-tissues and organs. When the immune system
malfunctions, cells (T Cells) attack self-tissues and organs, causing
autoimmune disease. Current autoimmune disease therapies suppress the
immune system, helping to minimize these self-attacks, but also raise
susceptibility to harmful foreign pathogens. Immunomodulation, the process
in which the immune system reduces self-attacks while properly reacting to
fight foreign pathogens, holds great potential for autoimmune disease.

About Artax-158
AX-158 is a first-in-class, oral small molecule, preclinical
immunomodulating agent in development for the treatment of autoimmune
diseases. AX-158 employs a novel mechanism of action that selectively
modulates, or adjusts, T cell responses that play a critical role in immune
system function. By selectively inhibiting Nck, a protein, AX-158 selectively
modulates self-directed T Cell activation which is a cause of autoimmune
disease. Importantly, data suggest AX-158 is not immunosuppressive and
does not impact the immune system’s ability to mount a strong response to
foreign pathogens and infections. Further, AX-158’s ability to modulate T cell
responses allows the possibility to broadly target several autoimmune
diseases, therefore potentially transforming autoimmune disease treatment.

About Artax Biopharma
Artax Biopharma is a biotechnology company transforming
autoimmune disease treatment. Artax is a life science industry leader in
autoimmune disease immunomodulation science, developing an
innovative small molecule approach to treat autoimmune disease that
modulates the immune system to both treat autoimmune disease and
allow the body to fight foreign pathogens. The company is examining a
first-in-class oral immunomodulating agent as a new way to treat multiple
autoimmune diseases without causing the immune suppression commonly
associated with currently available autoimmune disease therapies. For
more information, please visit www.artaxbiopharma.com.

Contacts:
Karen LaRochelle, MBA
Chief Business Officer
Artax Biopharma
klarochelle@artaxbiopharma.com

Media:
Linda Phelan Dyson, MPH
+1 973-986-5873
ldyson@artaxbiopharma.com

Jun 04
Love0

Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy

By Artax Biopharma, Press Release, Private Companies
Press Release.

 

– Extension Brings in Additional Investor –

Cambridge, MA, June 4, 2020 – Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the completion of an extension to its Series B financing led by Columbus Venture Partners.

AX-158 is a first-in-class, oral small molecule, immunomodulating agent in development for the treatment of autoimmune diseases. AX-158 employs a novel mechanism of action that selectively modulates, or adjusts, T cell responses that play a critical role in immune system function.  Proceeds from the financing will be used to support activities for a planned Q4 2020 filing of a Clinical Trial Application (CTA) with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for AX-158.

“We are pleased to welcome Columbus Venture Partners as a new investor,”

said Joseph Lobacki, Chief Executive Officer of Artax Biopharma.

“The support of Columbus Venture Partners is a testament to the transformative potential of our science, which has the potential to address autoimmune disease without causing immunosuppression.

” Javier García, Founder and Partner with Columbus Venture Partners, stated, “Columbus Venture Partners is pleased to have led the extension to this round of financing. We believe Artax’s highly experienced leadership team is well positioned to deliver on a truly innovative therapeutic program.”

About Immunomodulation

A healthy immune system eliminates harmful foreign pathogens, while being tolerant of self-tissues and organs.  When the immune system malfunctions, cells (T Cells) attack self-tissues and organs, causing autoimmune disease. Current autoimmune disease therapies suppress the immune system, helping to minimize these self-attacks, but also raise susceptibility to harmful foreign pathogens.Immunomodulation, the process in which the immune system reduces self-attacks while properly reacting to fight foreign pathogens, holds great potential for autoimmune disease therapies.

About Artax-158

AX-158 is a first-in-class, oral small molecule, preclinical immunomodulating agent in development for the treatment of autoimmune diseases. AX-158 employs a novel mechanism of action that selectively modulates, or adjusts, T cell responses that play a critical role in immune system function. By selectively inhibiting Nck, a protein, AX-158 selectively modulates self-directed T Cell activation which is a cause of autoimmune disease. Importantly, data suggests that AX-158 is not immunosuppressive and does not impact the immune system’s ability to mount a strong response to foreign pathogens and infections. Further, AX-158’s ability to modulate  T  cell  responses  allows  the  possibility  to  broadly  target  several autoimmune diseases, therefore potentially transforming autoimmune disease treatment.

About Artax Biopharma

Artax Biopharma is a biotechnology company transforming autoimmune disease treatment.  Artax is a life science industry leader in autoimmune disease immunomodulation science, developing an innovative small molecule approach to treat autoimmune disease that modulates the immune system to both treat autoimmune disease and allow the body to fight foreign pathogens.  The company is examining a first-in-class oral immunomodulating agent as a new way to treat multiple  autoimmune  diseases  without  causing  the  immune  suppression commonly associated with currently available autoimmune disease therapies. For more information, please visit www.artaxbiopharma.com.

Contacts:
Karen LaRochelle, MBA
Chief Business Officer
Artax Biopharma
klarochelle@artaxbiopharma.com

Media:
Linda Phelan Dyson, MPH
+1 973-986-5873
ldyson@artaxbiopharma.com

May 21
Love0

Amphista Therapeutics appoints leading protein degradation pioneer, Ian Churcher as CSO

By Amphista Therapeutics, Press Release, Private Companies
Press Release.

 

Glasgow, Scotland, 21 May 2020 – Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove disease causing proteins selectively and efficiently, today announced the appointment of Dr Ian Churcher as Chief Scientific Officer (CSO).

Amphista’s CEO Dr Nicola Thompson said,

“I’m delighted to welcome Ian to the team. As an internationally recognised leader in the field of targeted protein degradation (TPD) as a therapeutic modality, Ian’s scientific leadership will be a tremendous addition to the Amphista team as we progress our TPD pipeline to the clinic. Ian’s appointment so soon after last month’s $7.5m Series A financing signals Amphista’s determination to deliver on its vision to create a world-leading protein degradation company delivering ground-breaking new medicines in areas of high patient need.”

Ian commented on his appointment,

“I’ve long sought out novel approaches to address traditionally undruggable targets in areas of high patient need. Amphista has a unique approach to targeted protein degradation and Nicola has quickly built a high-quality team. I’m excited by the opportunity to help Amphista develop its novel platform further and rapidly advance its lead projects into the clinic. As Amphista’s approach is very different to existing targeted degradation approaches, it offers significant potential to address a wide range of targets to ultimately help patients across many hard to treat diseases.”

Between 2012-2017, Ian led the Protein Degradation Discovery Performance Unit at GSK where, in collaboration with Professors Craig Crews and Alessio Ciulli, they pioneered the use of VHL-dependent PROTACs, culminating in landmark publications. Ian has also led teams developing drug discovery technologies and advancing medicines across multiple therapy areas during an R&D career at Merck & GSK. More recently, Ian led research at biotechnology companies aiming to change the way drug R&D is carried out, including as SVP Drug Discovery at BenevolentAI. There, working closely with machine learning and data science experts, he advanced a portfolio of programmes and helped develop novel AI-led methods for target identification and chemical optimisation. Ian holds an MA and D.Phil. in Chemistry from the University of Oxford where he was also Visiting Professor in the Department of Chemistry.

Amphista’s TPD small molecules instruct cells to degrade disease-causing target proteins directly, giving a clear therapeutic advantage over simple target inhibition. Specifically, Amphista’s platform is independent of traditional E3 ubiquitin ligases used by the field, potentially expanding the available target scope of TPD approaches and should overcome recently identified PROTAC® resistance mechanisms.

–    Ends   –

Media contacts:

Amphista Therapeutics
CEO NicolaThompson
+447464974714
nicki@amphista.com

Scius Communications
Katja Stout
+447789435990
katja@sciuscommunications.com

About Amphista Therapeutics

Amphista Therapeutics is a biopharmaceutical company creating first-in-class therapeutics that help harness the body’s natural processes to selectively and efficiently degrade and remove disease causing proteins. The company’s pipeline of novel small molecules that cause targeted protein degradation (TPD) is focused on challenging diseases including cancer. Amphista is a spin-out of renowned TPD expert Professor Alessio Ciulli’s labs at the University of Dundee, and is based in BioCity Glasgow, Scotland. The company is funded by leading life science investors including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and BioMotiv. For more information, visit http://www.amphista.com/

May 13
Love0

Artax Biopharma Appoints Joseph Lobacki as Chief Executive Officer, Announces Expanded Management Team

By Artax Biopharma, Press Release, Private Companies
Press Release.

 

Autoimmune Disease Company Hires Life Science Industry Experts to Lead Company
Through Next Stage into Human Clinical Studies with Novel Oral Small Molecule AX-158

Cambridge, MA, May 13, 2020 – Artax Biopharma, Inc., a biotechnology company
focused on transforming autoimmune disease treatment, announces their
expanded management team, being led by newly appointed Chief Executive Officer
(CEO) Joseph Lobacki. Comprised of immunology industry leaders and scientists,
the team represents deep expertise in drug discovery, development and
collaborations from some of the world’s most prestigious institutions.

Artax Biopharma is poised to enter clinical trials with the small molecule AX-
158, a novel approach to treat multiple autoimmune diseases without causing the
immune suppression commonly associated with current autoimmune disease
therapies.

Joseph Lobacki assumes the helm of Artax Biopharma after more than three
decades of leadership including research, development, and commercial
experience in executive roles across large and small biopharmaceutical companies,
including Sanofi Genzyme, Medivation, Verastem, and Micromet. The former CEO,
Damia Tormo, will continue as a member of the Board of Directors and we thank
Dr. Tormo for his years of work in founding and building Artax.

“We are thrilled to have such a strategic and experienced leader as Joseph
Lobacki steering Artax from our new US headquarters at this seminal time,”

stated Artax Biopharma’s Executive Chairman of the Board Alan Walts, Ph.D.

“His deep experience will prove invaluable as Artax’s first oral agent to treat autoimmune
disease prepares to enters the clinic.”

The Artax Biopharma management team includes Joseph Lobacki, CEO; Chris
VanDeusen, Ph.D., Chief Scientific Officer (CSO); Richard P. Polisson, M.D., MHSc,Chief Medical Officer (CMO); Karen LaRochelle, MBA, Chief Business Officer (CBO), and Andres Gagete, Ph.D., Chief Operating Officer, (COO).

“I am excited to lead these incredibly talented and experienced professionals
in our Cambridge location as we fulfill the Artax mission to make our treatments
available as quickly as possible to patients who suffer from autoimmune diseases.
This team possesses the critical knowledge and experience to progress our novel
immunomodulator into clinical development and to drive this important mission
forward,”

added Mr. Lobacki.

Prior to Artax, Mr. Lobacki most recently served as Executive Vice President
and Chief Commercial Officer for Verastem, Inc.; Chief Operating Officer of Finch
Therapeutics Group, and Chief Commercial Officer and Executive Council Member
of Medivation, where he led a period of strong revenue growth for prostate cancer
treatment Xtandi®. Mr. Lobacki also held previous roles as Senior Vice President
and Chief Commercial Officer of Micromet, Inc., and Senior Vice President and
General Manager at Genzyme Corporation. Mr. Lobacki served as a director of
Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals) and is currently on the
Boards of Sutro Biopharma and Artax Biopharma.

As CSO, Dr. VanDeusen will lead Artax’s scientific, research and translational
areas. Dr. VanDeusen brings more than 15 years of biopharmaceutical experience
and extensive expertise in drug discovery and development. He is also an inventor
and key contributor to multiple preclinical development compounds. Previously,
Dr. VanDeusen headed the chemistry division and was a global project team leader
within Tissue Protection and Repair at Sanofi Genzyme.
Dr. Polisson, in his role as Artax’s CMO, will direct the company’s clinical
development strategy. With 30 years of clinical and translational research
experience, Dr. Polisson joins Artax from the Sanofi Genzyme Research and
Development Center where he was Senior Vice President and Translational
Medicine Head directing discovery and translational medicine efforts across
multiple therapeutic areas. Previously, Dr. Polisson served as Associate Professor
of Medicine, Arthritis Unit Clinical Director at Massachusetts General Hospital and
Harvard Medical School.

As Chief Business Officer, Karen LaRochelle, MBA will lead all partner- and
investor-related interactions. With more than 25 years of biopharmaceutical
strategy and collaborations experience, her expertise in mergers & acquisitions
includes a deep history transacting for biotech companies, with several
transactions exceeding $1 billion. Prior to Artax, Ms. LaRochelle was Chief Business
Officer of PsiOxus Therapeutics. Previously in her career, Ms. LaRochelle spent
nearly 20 years with Bristol-Myers Squibb focused on strategy and transactions.

Dr. Gagete, as Artax’s COO, is currently coordinating research &
development and operations for Artax. Dr. Gagete has more than a decade of
experience in the biotech and academic sectors and was previously the Innovation
Director for Bioncotech Therapeutics.

About Immunomodulation

A healthy immune system eliminates harmful foreign pathogens, while being
tolerant of self-tissues and organs. When the immune system malfunctions, cells
(T Cells) attack self-tissues and organs, causing autoimmune disease. Current
autoimmune disease therapies suppress the immune system, helping to minimize
these self-attacks, but also raise susceptibility to harmful foreign pathogens.
Immunomodulation, the process in which the immune system reduces self-attacks
while properly reacting to fight foreign pathogens, holds great potential for
autoimmune disease.

About Artax-158

AX-158 is a first-in-class, oral small molecule, preclinical immunomodulating
agent in development for the treatment of autoimmune diseases. AX-158 employs
a novel mechanism of action that selectively modulates, or adjusts, T cell responses
that play a critical role in immune system function. By selectively inhibiting Nck, a
protein, AX-158 selectively modulates self-directed T Cell activation which is a
cause of autoimmune disease. Importantly, AX-158 is not immunosuppressive and
does not impact the immune system’s ability to mount a strong response to foreign
pathogens and infections. Further, AX-158’s ability to modulate T cell responses
allows the possibility to broadly target several autoimmune diseases, therefore
potentially transforming autoimmune disease treatment.

About Artax Biopharma

Artax Biopharma is a biotechnology company transforming autoimmune
disease treatment. Artax is a life science industry leader in autoimmune disease
immunomodulation science, developing an innovative small molecule approach to
treat autoimmune disease that modulates the immune system to both treat
autoimmune disease and allow the body to fight foreign pathogens. The company
is examining a first-in-class oral immunomodulating agent as a new way to treat
multiple autoimmune diseases without causing the immune suppression
commonly associated with currently available autoimmune disease therapies. For
more information, please visit www.artaxbiopharma.com.

Contacts:
Karen LaRochelle, MBA
Chief Business Officer
Artax Biopharma
klarochelle@artaxbiopharma.com

Media:
Linda Phelan Dyson, MPH
+1 973-986-5873
ldyson@artaxbiopharma.com

Apr 23
Love0

Nalu Medical, Inc. Appoints New Chief Executive Officer: Earl R. Fender Joins as President & CEO

By Nalu Medical, Press Release, Private Companies
Press Release.

 

CARLSBAD, Calif. (PRWEB) April 23, 2020

Nalu Medical, Inc. (“Nalu”), a global medical device company that provides miniaturized, battery-free implantable solutions for the treatment of chronic pain in Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), announced today that Earl R. Fender has been appointed President and Chief Executive Officer and member of the Board of Directors. Mr. Fender succeeds Keegan Harper, who has stepped down as CEO but will remain as Chairman of the Board.

“We are very excited to welcome Earl Fender to the Nalu team,”

said Mr. Harper.

“I cannot think of a stronger person to lead Nalu as it enters its full commercialization and growth phase than Earl. He brings over 30 years of successful experience in building and leading medical technology companies. For the last 12-years, he worked in the chronic pain space as the CEO of Vertiflex, Inc., which was acquired by Boston Scientific in June 2019. He brings a wealth of experience in building industry-leading, high growth companies and I am excited to have him join the Nalu team.”

“I am very excited and proud to join Nalu’s illustrious team who has developed such differentiated technology to positively impact the lives of patients in the U.S. and abroad,”

said Mr. Fender.

“The uniquely miniaturized, battery-free and easily upgradable Nalu implantable pulse generator system will help expand patient acceptance in both spinal cord and peripheral nerve stimulation.”

“We are very excited to welcome Earl Fender to the Nalu team. I cannot think of a stronger person to lead Nalu as it enters its full commercialization and growth phase than Earl. He brings over 30 years of successful experience in building and leading medical technology companies.”

Mr. Fender added,

“The Board thanks Keegan for his years of dedicated service to Nalu since founding the Company in 2014. As Nalu’s co-founder and CEO, Keegan built a strong team, developed a sophisticated product in record time, launched a successful first in human study in Australia, received FDA clearance in SCS and PNS, received CE mark approval, and completed a successful limited clinical launch in the U.S. We look forward to his continued leadership as Nalu’s Chairman.”

About the Nalu Neurostimulation System
The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The system is highly capable and easily upgradeable, providing a menu of therapy options. To learn more, please visit http://www.nalumed.com.

About Nalu Medical
Nalu Medical, Inc. is a privately held early-stage medical device start-up company based in Carlsbad, California. The team of seasoned entrepreneurs, engineers and scientists are developing the next generation of medical devices to address a number of poorly treated clinical conditions. Nalu Medical’s vision is to modernize and enhance medical device technology to improve people’s lives.

Apr 17
Love0

Highlight Therapeutics appoints Dr. Carlos Paya as Executive Chairman

By Highlight Therapeutics, Press Release, Private Companies
Press Release.

 

Dr Ralph Weichselbaum, Dr.Antoni Ribas & Michael Docherty appointed to SAB

Company renamed to Highlight Therapeutics

Madrid,  Spain –April  17, 2020: Highlight Therapeutics (“Highlight”), a clinical-stagebio pharmaceutical company developing RNA-based therapies against cancer,announces the appointment of Carlos Paya, MD, PhD,as Executive Chairman with immediate effect.The Company has also significantly expanded its Advisory Board with a number of internationally-renowned scientific and industry leaders.  In line with these changes, the  Company has  been  renamed from Bioncotech Therapeutics  to  Highlight Therapeutics – see separate press release.

Marisol  Quintero, CEO of Highlight, said:

“Dr Paya’s impressive industry experience,  his  track  record  of guiding biotech companies through product development to global launch and his extensive reach with both scientists and investors will all be of great assistance to Highlight at this important point in our development. In  addition,  we have significantly expanded our Advisory  Board with distinguished scientists and  industry specialists of the highest caliber. These key appointments provide Highlight with the broad range of skills and know how to drive our ambition to unlock thepotential of immunotherapy for many more patients.”

Dr. Paya has a distinguished track record of leadership in large-cap pharma and mid-cap biotech and start-up companies, with a focus on strategic execution, pipeline growth, product life cycle management and global product launches, as well as a number of successful public and private fundraises.

He is a director of Mallinckrodt Pharmaceuticals and of Fluidigm Corporation. Previously, he was president, chief executive officer and board member of Immune Design Corp., a late-stage immunotherapy company, from  May  2011  until  its  acquisition  by  Merck  &  Co.,  Inc.  in  April  2019.He held  leadership  roles  at Elan Pharmaceuticals and Eli Lilly and Co. in discovery research and clinical development. Prior to  his  industry roles, Dr.  Paya spent  nearly  a  decade  at  the  Mayo  Clinic-Rochester, including as professor of medicine, immunology and pathology and vice dean of the clinical investigation program.

Dr Paya received his medical and doctorate degrees from the Universidad Complutense of Madrid Medical School, and completed his specialty training in Internal Medicine, Infectious Diseases and Immunology at the Mayo Graduate  School of  Medicine.  He was a research scientist in a  post-doctoral  position at Institute Pasteur in Paris and completed the advanced management program at the University of Chicago’s Booth School of Business.

The Company’s Scientific Advisory Board has expanded and now comprises:

Ralph R. Weichselbaum MD

  • Professor of Radiation & Cellular OncologyChair, Department of Radiation & Cellular Oncology, University of Chicago
  • Made discoveries in basic signal transduction after ionizing radiation exposure &, in separate studies, discovered that mechanisms of radiation resistance/sensitivity are mediated by cytokine activation in tumors
  • Currently investigating the relationship between radiotherapy & immunotherapy

Antoni Ribas MD, PhD

  • Professor of Medicine, Professor of Surgery & Professor of Molecular & Medical Pharmacology at UCLA
  • Director of Tumor Immunology Program at Jonsson Comprehensive Cancer Center
  • Director of Parker Institute for Cancer Immunotherapy Center, UCLA
  • Chair of SWOG Melanoma Committee; member of American Society of Clinical Investigation
  • Recipient of AACR Richard & Hinda Rosenthal Award & NCI Outstanding Investigator Award

Michael Doherty

  • Led Global Regulatory Affairs function at Roche & launched first oncology portfolio with a franchise of monoclonal antibodies and targeted medicines
  • Member of the Roche portfolio committee from 2002 to 2016
  • Prior positions: Global Head, Pharma Regulatory Affairs
  • Hoffmann La-Roche Ltd., Basel/Genentech, San Francisco
  • Head Product Development Foundation Medicine

For more information, please contact:

Highlight Therapeutics, Marisol Quintero, CEO info@highlight.com

Mo PR Advisory, Mo Noonan / Jonathan Birt Tel: +44 (0) 7876 444977/ 07860 361746

 

Notes to Editors

About Highlight Therapeutics

Highlight, formerly known as Bioncotech Therapeutics S.L, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Itslead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging aunique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to theimmune system. It has the potential to rescue patients who are resistantto current checkpoint inhibitor therapy, a very large market opportunity. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint  inhibitors.  In  addition  to  in-house  research,  Highlight  Therapeutics  has  a  numberof  external collaborators, including Merck & Co and UCLA

Apr 17
Love0

Highlight Therapeutics announces name change from Bioncotech and launch of new website

By Highlight Therapeutics, Press Release, Private Companies
Press Release.

 

Madrid,  Spain –April 17,  2020:Highlight Therapeutics, a  clinical-stagebio pharmaceutical  company developing RNA-based therapies against cancer, announces that  it has changed its name  from Bioncotech with immediate effect. The company has launched a new corporate website, www.highlighttherapeutics.com, and related rebranding.

Highlight  Therapeutics  also announced  that  clinical  trials  of  its  lead  product  candidate  BO-112  will  be classified numerically under the umbrella name Spotlight for ease of identification.

BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate  a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune  system.It  has  the  potential  to  rescue  patients  who are resistant to current  checkpoint  inhibitor therapy, a very large market opportunity. BO-112 is currently being investigated in a range of clinical trials as  a  monotherapy and  in  combination with  checkpoint  inhibitors by Highlight Therapeutics  and  external collaborators including MSD, a subsidiary of Merck & Co., Inc, and UCLA.

Marisol Quintero, CEO of Highlight Therapeutics, commented:

“BO-112 highlights tumor cells,making them visible to the immune system.Our new identity as Highlight Therapeutics, and the branding of our expanding clinical  trial  program under  the Spotlight banner,  are  a clear representation  of  our  focus  and  the  unique approach we are taking to unlock the potential of checkpoint inhibitors in immunotherapy.

“Highlight Therapeutics has developed an extensive preclinical  package  differentiating BO-112 from other innate immune activators.  We are launching our new name at amajor inflection point in the development of  our  portfolio  as  we  work  to expand  on our initial  findings  and  apply  intratumoral  immunotherapy  to indications where we believe it has the potential to benefit many more patients, including liver metastases and melanoma.”

For more information, please contact:

Highlight Therapeutics S.L- Marisol Quintero, CEO info@highlight.com

Mo PR Advisory – Mo Noonan / Jonathan Birt Tel: +44 (0) 7876 444977/ 07860 361746

Notes to Editors

About Highlight Therapeutics

Highlight, formerly known as Bioncotech Therapeutics S.L, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Its lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging aunique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy, a very large market opportunity. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint  inhibitors.  In addition to in-house  research,  Highlight  Therapeutics  has  a  numberof  external collaborators, including Merck & Co and UCLA.

Apr 15
Love0

PIC Therapeutics Raises $5 Million to Advance Development of Small Molecules That Selectively Modulate eIF4E

By PIC Therapeutics, Press Release, Private Companies
Press Release.

 

Series Seed Equity Round led by Advent Life Sciences

BOSTON–(BUSINESS WIRE)–PIC Therapeutics (“PIC”), a biotechnology company focused on transforming the treatment of cancer though the selective
modulation of oncogene translation, closed a $5M Series Seed round of preferred equity funding.

The oversubscribed round was led by Advent Life Sciences (“Advent”), and included participation by Belinda Termeer, widow of legendary Genzyme CEO Henri Termeer, as well as several biopharmaceutical industry executives and other individual investors.

PIC Therapeutics was founded based on the extensive research of scientific founder Professor Gerhard Wagner of Harvard University and is led by founding CEO Sun Altbach, a 20+ year life sciences veteran and by Dr. Alan Walts, Executive Chairman and Venture Partner at Advent Life Sciences.PIC is supported by a world-renowned Scientific Advisory Board and Board of Directors.

PIC targets the “master switch” of cancer signaling pathways, blocking oncogene protein production by selectively modulating the Pre-Initiation Complex (PIC), specifically eIF4E – a convergence point driving oncogene RNA translation. PIC Therapeutics’ targeted approach has the potential to simultaneously impact multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics that address drug resistance and tumor heterogeneity, issues that plague many existing treatments.

Sun Altbach, CEO commented,

“This is an important step for PIC as we seek to transform how cancer is treated and therefore make a significant difference in patients’ lives. With this funding in hand we can accelerate our program focusing on allosteric regulation of eIF4E via an innovative drug development platform designed to produce early proof of concept in advance of the clinic.”

Alan Walts, Executive Chairman and Venture Partner at Advent added,

“PIC is a leader in the rapidly advancing field of translational modulation of oncogenes. PIC has developed a best in class portfolio of proprietary small molecule modulators of eIF4E and a comprehensive platform to validate human tumor activity. We are pleased to support their efforts to develop a new class of cancer therapies.”

PIC’s Board of Directors consists of:

  • Alan Walts, PhD, Executive Chairman of the Board; Venture Partner, Advent Life Sciences
  • Sun Altbach, MBA, CEO and President, PIC Therapeutics
  • Richard Peters, MD, PhD, Co-Founder, PIC Therapeutics; CEO Yumanity Therapeutics
  • Belinda Termeer, Termeer Foundation
  • Gerhard Wagner, PhD, Co-Founder, PIC Therapeutics; Elkan Rogers Blout Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

PIC’s Scientific and Corporate Advisory Board consists of:

  • Keith Flaherty, MD, Director of Clinical Research at the Cancer Center at MGH
  • Jennifer Petter, PhD, Founder and Chief Scientific Officer of Arrakis Therapeutics
  • Nahum Sonenberg, PhD, Biochemistry Professor and Gilman Cheney Chair, McGill University
  • Yat Sun Or, PhD, Chief Scientific Officer, Enanta Pharmaceuticals
  • Jan Van Heek, MBA, Board Member, Amarin Corporation and Minerva Neuroscience
  • Gerhard Wagner, PhD, Co-Founder, PIC Therapeutics; Elkan Rogers Blout Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

 

About PIC Therapeutics

PIC Therapeutics is a Boston, MA-based biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation. PIC’s therapeutics target the “master switch” of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. PIC Therapeutics’ selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.

PIC is guided by a dedication to improving cancer patient outcomes and to realizing the potential of our technology to their benefit.

www.pictherapeutics.com

About Advent Life Sciences

Advent Life Sciences founds and invests in early- and mid-stage life sciences companies that have a first- or best-in-class approach to unmet medical needs. The investing team consists of experienced professionals, each with extensive scientific, medical and operational experience, a long-standing record of entrepreneurial and investment success in the US and Europe and is particularly focused on supporting entrepreneurs and founders to take innovative new medical entities from concept to approval. The firm invests in a range of sectors within life sciences, principally drug discovery, enabling technologies and med tech, always with an emphasis on innovative, paradigm-changing approaches. Advent Life Sciences has a presence in the UK, US and France. For more information, please visit

www.AdventLS.com.

Contacts
PIC Therapeutics
Sun Altbach, CEO and President
info@pictherapeutics.com
+1 617-637-378